Aptevo Therapeutics (APVO) Leases (2019 - 2023)
Historic Leases for Aptevo Therapeutics (APVO) over the last 5 years, with Q3 2023 value amounting to $5.0 million.
- Aptevo Therapeutics' Leases fell 769.23% to $5.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $5.0 million, marking a year-over-year decrease of 769.23%. This contributed to the annual value of $5.3 million for FY2022, which is 23478.54% up from last year.
- As of Q3 2023, Aptevo Therapeutics' Leases stood at $5.0 million, which was down 769.23% from $5.1 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Leases high stood at $5.5 million for Q2 2022, and its period low was $1.3 million during Q1 2022.
- Its 5-year average for Leases is $3.7 million, with a median of $3.7 million in 2019.
- As far as peak fluctuations go, Aptevo Therapeutics' Leases tumbled by 4658.49% in 2022, and later skyrocketed by 29816.23% in 2023.
- Over the past 5 years, Aptevo Therapeutics' Leases (Quarter) stood at $3.7 million in 2019, then decreased by 27.36% to $2.7 million in 2020, then crashed by 41.81% to $1.6 million in 2021, then soared by 234.79% to $5.3 million in 2022, then dropped by 5.86% to $5.0 million in 2023.
- Its Leases stands at $5.0 million for Q3 2023, versus $5.1 million for Q2 2023 and $5.2 million for Q1 2023.